Bristol Myers Squibb Co. Hits New 52-Week Low at $42.52

Bristol Myers Squibb Co., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 42.52 on October 29, 2025. This marks a significant decline from its 52-week high of USD 63.33, reflecting the stock's volatility over the past year.
In terms of financial metrics, Bristol Myers Squibb boasts a market capitalization of approximately USD 127,940 million, categorizing it as a large-cap company. The stock currently has a price-to-earnings (P/E) ratio of 15.00, which is indicative of its valuation relative to earnings. The company also offers a substantial dividend yield of 80.34%, appealing to income-focused investors.

Despite the recent price movement, Bristol Myers Squibb has demonstrated a return on equity of 51.19%, showcasing its efficiency in generating profits from shareholders' equity. However, the company's debt-to-equity ratio stands at 2.05, suggesting a higher reliance on debt financing compared to equity. Over the past year, the stock has shown a modest performance of 0.07%, significantly lagging behind the S&P 500's performance of 18.33%.